Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Gini F. Fleming et al.|The Lancet Oncology|2019Cited by 533
Conservative management of morbidly adherent placenta: expert reviewKarin A. Fox, Michael A. Belfort, Alireza A. Shamshirsaz et al.|American Journal of Obstetrics and Gynecology|2015Cited by 208
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centersAmanda N. Fader, Paola A. Gehrig, Leigh G. Seamon et al.|Gynecologic Oncology|2012Cited by 109
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.Ursula A. Matulonis, Daniela Matei, Amit M. Oza et al.|Journal of Clinical Oncology|2016Cited by 8